Kiora Pharmaceuticals Inc (KPRX) stock
KPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as KPHMW
$0.93−0.05 (-5.30%)
Close on Nov 17, 2026Market cap $4.11MP/E –Yield –
Kiora Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Kiora Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$12.79M. For fiscal 2025 it was -$12.81M, down 382.7% from the year before. The highest annual figure on record is $4.53M in fiscal 2024.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.81M | -382.7% |
| FY2024 | Dec 31, 2024 | $4.53M | – |
| FY2023 | Dec 31, 2023 | -$12.54M | – |
| FY2022 | Dec 31, 2022 | -$12.27M | – |
| FY2021 | Dec 31, 2021 | -$14.19M | – |
| FY2020 | Dec 31, 2020 | -$6.84M | – |
| FY2018 | Dec 31, 2018 | -$10.81M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.20M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.50M | – |
| Q4 FY2025 | Dec 31, 2025 | -$7.30M | – |
| Q3 FY2025 | Sep 30, 2025 | -$783.89K | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.39M | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.33M | -117.6% |
| Q4 FY2024 | Dec 31, 2024 | -$2.56M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.60M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.54M | – |
| Q1 FY2024 | Mar 31, 2024 | $13.23M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.11M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.91M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.61M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.91M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.62M | – |
| Q3 FY2022 | Sep 30, 2022 | -$3.69M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.39M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.56M | – |
| Q4 FY2021 | Dec 31, 2021 | -$6.36M | – |
| Q3 FY2021 | Sep 30, 2021 | -$3.02M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.81M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.00M | – |
| Q4 FY2020 | Dec 31, 2020 | -$1.16M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.00M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.71M | -303.5% |
| Q1 FY2020 | Mar 31, 2020 | -$1.96M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.44M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.86M | – |
| Q1 FY2019 | Mar 31, 2019 | $841.56K | – |
| Q4 FY2018 | Dec 31, 2018 | -$2.48M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.17M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.79M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.37M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.14M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.32M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.92M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.38M | – |
See a number that looks wrong?